A Study of FDA022-BB05 in Advanced/Metastatic Solid Tumors - Trial NCT06413615
Access comprehensive clinical trial information for NCT06413615 through Pure Global AI's free database. This Phase 2 trial is sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. and is currently Not yet recruiting. The study focuses on Advanced Solid Tumor. Target enrollment is 150 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Timeline & Enrollment
Phase 2
May 13, 2024
Jun 30, 2026
Primary Outcome
Objective Response Rate (ORR),Occurrence of adverse events (AEs) and serious adverse events (SAEs)
Summary
This is an open-label, multicenter, Phase II study to evaluate the efficacy and safety of
 FDA022-BB05 for the treatment in locally advanced, unresectable, or metastatic patients with
 selected HER2 overexpressing/expressing solid tumors which are not eligible for curative
 therapy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06413615
Non-Device Trial